Showing results (111-120 of 165) with videos related to
Sort By:
Pageof 17
Leukemia & Lymphoma|December 4, 2013
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)Silvia Govi, David Christie, Silvia Mappa, et al.Blood|September 29, 2020
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphomaPamela B Allen, Hatice Savas, Andrew M Evens, et al.JAMA Oncology|March 17, 2023
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical TrialLocke J Bryan, Carla Casulo, Pamela B Allen, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 28, 2014
A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage diseaseDolores Grosso, Sameh Gaballa, Onder Alpdogan, et al.Journal of Transplantation|January 7, 2026
Posttransplant Lymphoproliferative Disorder (PTLD): 24 Years of Experience at a Referral Center in São Paulo, Brazil. Can Differences in Prevalence and Subtype of EBV Infection in the Population Influence the Results? A Retrospective Cohort StudyJuliano Córdova Vargas, Ricardo Helman, Marcelino de Souza Durão, et al.British Journal of Haematology|December 3, 2015
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trialRanjana H Advani, Stephen M Ansell, Mary J Lechowicz, et al.Haematologica|January 29, 2008
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experiencePaolo Anderlini, Rima Saliba, Sandra Acholonu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor projectMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy, Anas Younes, Peter McLaughlin, et al.Blood Advances|July 24, 2025
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and EfficacyOluwatobi Odetola, Shuo Ma, Jane N Winter, et al.Pageof 17